Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410001 | 0.93 | HCRTR1 (0.42) | HCRTR1HCRTR2GAATSHR | |
| SCHEMBL1967471 | 0.92 | CHRM5 (0.42) | HCRTR1HCRTR2LPAR1LPAR5MAPT | |
| SCHEMBL2407884 | 0.91 | TP53 (0.42) | HCRTR1HCRTR2GAALPAR1LPAR5 | |
| SCHEMBL1969317 | 0.91 | HCRTR1 (0.43) | HCRTR1HCRTR2GAALPAR1LPAR5 | |
| SCHEMBL1970040 | 0.89 | HCRTR1 (0.38) | HCRTR1HCRTR2GAALPAR1LPAR5 | |
| SCHEMBL1967329 | 0.87 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL1969287 | 0.86 | KDM4E (0.41) | HCRTR1HCRTR2MAPTKMT2AMEN1 | |
| SCHEMBL1969373 | 0.85 | LPAR1 (0.43) | HCRTR1HCRTR2GAALPAR1LPAR5 | |
| SCHEMBL1969020 | 0.84 | HCRTR1 (0.42) | HCRTR1HCRTR2GAALPAR1LPAR5 | |
| SCHEMBL1967039 | 0.83 | HCRTR1 (0.51) | HCRTR1HCRTR2LPAR1LPAR5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885GAA 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.